Apple Peptide Complex for Post-Surgical and Aesthetic Skin Recovery

NCT07807085 | Completed

• 1 other identifier: GOO-APPLE-PEPTIDE-001
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

This clinical study evaluates a topical botanical formulation for supporting skin recovery following invasive and non-invasive aesthetic procedures. These procedures include liposuction, breast augmentation, Brazilian butt lift (BBL), laser treatments, and micro needling, pregnancy stretch mark and weight loss skin. The study will assess the effects of the formulation on skin elasticity, hydration, and overall appearance when used as part of post-procedure care under the supervision of licensed medical professionals. Participants will apply the product to treatment areas over a defined study period, and outcomes will be compared to a control group receiving standard care or placebo.

Conditions

Skin Barrier to Water Loss; Skin Health; Skin Discoloration; Skin Irritation; Skin Abnormalities; Hyperpigmentation; Hyperpigmentation; Melanin; Stretch Mark; Breast Reconstruction; Breast Augmentation and Breast Reconstruction; Chemotherapy Effects; Lymphatic Abnormalities

Keywords

aesthetic care healing modality; bbl post care treatment; breast augmentation and reconstructive post care treatment; stretch marks; skin hyperpigmentation; skin irritation; skin barrier health; skin discoloration

Outcome Measures

Primary Outcomes (3)

• Clinician-Graded Visual Skin Evaluation Score

  Clinician assessment of skin surface appearance to monitor reductions in post-procedural redness and dryness. Evaluation is performed using a standard 0 to 4 scale, where 0 indicates no redness/dryness and 4 indicates severe redness/dryness. Unit of Measure: Units on a scale (0 to 4)

  Baseline, Day 14, and Day 28 post-procedure

• Change in Trans epidermal Water Loss (TEWL)

  Evaluation of skin barrier function following daily topical use of the cosmetic Apple Peptide Complex. Data are collected via a tewameter to assess absolute changes in skin moisture retention. Unit of Measure: g/h/m²

  28 days post-procedure (with assessments conducted at day 14 and day 28)

• Participant Comfort Rating Score

  Self-reported participant feedback regarding skin comfort, including soothing sensations and lack of irritation. Scores are recorded using a feedback scale from 0 (extreme discomfort/irritation) to 10 (complete skin comfort/highly soothed). Unit of Measure: Units on a scale (0 to 10)

  Baseline, Day 14, and Day 28 post-procedure

Secondary Outcomes (2)

• Presence of Post-Inflammatory Hyperpigmentation (PIH)Description

  Baseline (pre-procedure), immediately post-procedure, Day 14, and Day 28

• Clinician-Graded Skin Desquamation Score

  Baseline (pre-procedure), immediately post-procedure, Day 14, and Day 28

Other Outcomes (1)

• Clinician-Rated Skin Erythema Score

  Baseline (pre-procedure), immediately post-procedure, Day 14, and Day 28

Study Arms (1)

Apple Peptide Complex Post-Aesthetic Care Protocol

EXPERIMENTAL

Participants receive the Apple Peptide Complex topical formulation as a standardized post-aesthetic care intervention following an invasive or non-invasive aesthetic procedure. The formulation is applied to designated treatment areas according to the study protocol-defined frequency and duration. Participants are evaluated for predefined biomedical and/or health-related outcomes associated with post-procedural recovery and overall cellular repair.

Other: Apple Peptide Complex Post-Aesthetic Care Protocol

Interventions

Apple Peptide Complex Post-Aesthetic Care Protocol OTHER

Participants receive the Apple Peptide Complex topical formulation as a standardized post-aesthetic care intervention following invasive and non-invasive aesthetic procedures. Participants apply the formulation to designated treatment areas according to the protocol-defined frequency, amount, and duration. Outcomes are evaluated to assess the formulation's effects on post-procedural skin recovery and overall cellular repair. Apple Peptide Complex is administered topically as a standardized post-aesthetic care intervention following invasive and non-invasive aesthetic procedures. Participants apply the formulation to designated treatment areas according to protocol-defined instructions regarding frequency and duration. The study evaluates predefined outcomes associated with post-procedural recovery and overall cellular repair.

Apple Peptide Complex Post-Aesthetic Care Protocol

Eligibility Criteria

• Gender Eligibility Details: female
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Female participants aged 45-65 years
• Undergoing or have undergone aesthetic or surgical procedures (e.g., liposuction, breast augmentation, laser treatments, microneedling)
• Presence of skin concerns such as hyperpigmentation, scarring, or reduced elasticity
• Willing and able to comply with study procedures and follow-up
• Physician clearance for participation

You may not qualify if:

• Active skin infections, open wounds, or delayed wound healing
• Pregnancy or breastfeeding
• Use of conflicting topical or systemic treatments
• Known allergy to botanical ingredients in the formulation

Sponsors & Collaborators

• Grow Out Oils Clinical Aromatherapy Company: lead

Study Sites (1)

Grow Out Oils Clinical Aromatherapy Company

Weston, Florida, 33326, United States

Location

Related Publications (4)

• Proksch E, Brandner JM, Jensen JM. The skin: an indispensable barrier. Exp Dermatol. 2008 Dec;17(12):1063-72. doi: 10.1111/j.1600-0625.2008.00786.x.

  PMID: 19043850 RESULT

• Citation 3 (Post-Procedure Skin Care) Draelos ZD. The role of skin care in optimizing outcomes following cosmetic procedures. Journal of Cosmetic Dermatology. 2012;11(3):169-173.

  RESULT

• Pullar JM, Carr AC, Vissers MCM. The Roles of Vitamin C in Skin Health. Nutrients. 2017 Aug 12;9(8):866. doi: 10.3390/nu9080866.

  PMID: 28805671 RESULT

• Saxena S. Mobile pediatric service. Indian Pediatr. 1972 Nov;9(11):641-2. No abstract available.

  PMID: 4658681 RESULT

Related Links

• Grow Out Oils Company Website
• Investor-grade white paper detailing clinical rationale and study design available at:

MeSH Terms

Conditions

Skin Abnormalities; Hyperpigmentation; Striae Distensae; Lymphatic Abnormalities

Condition Hierarchy (Ancestors)

Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin Diseases; Skin and Connective Tissue Diseases; Pigmentation Disorders; Skin Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Lymphatic Diseases; Hemic and Lymphatic Diseases

Study Officials

• Shanna Bynes Bradford, Master Aromatherapy

  Grow Out Oils Clinical Aromatherapy Company

  PRINCIPAL INVESTIGATOR

• Dr. Lane Rolling MD, Virologist, Epidemiologist,

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Masking Details: This study was conducted as an open-label trial. Both participants and investigators were aware of the assigned treatment groups due to the nature of the topical intervention and standard care comparison.
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Participants were randomized into two parallel groups: an intervention group receiving the topical Apple Peptide Complex as part of post-procedural care, and a control group receiving standard post-procedure care. Both groups were monitored over the same study period following invasive and non-invasive aesthetic procedures, including surgical and dermatologic treatments, to evaluate skin recovery outcomes.

Study Record Dates

• First Submitted: April 27, 2026
• First Posted: September 8, 2026
• Study Start: January 20, 2021
• Primary Completion: December 4, 2025
• Study Completion: December 29, 2025
• Last Updated: September 8, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, ICF, CSR
• Time Frame: The only information that will be available with the (IPD) for supporting information will be the study protocol, clinical study report (CSR) and informed consent form (ICF)
• Access Criteria: Due to the nature of the patients privacy regulations and principles mandate by HIPAA the (IPD) details used for the clinical research will be limited based on the "need to know" and "minimum necessary".

Locations

US (1)